Search
for
Sort by
Research 271–300 of 1000+
- Associations Between Iron Metabolism and Obstructive Sleep Apnea Severity in Female and Male Individuals With Self‐Reported Androgenetic Alopecia: A Propensity‐Score Matching Analysis From the EPISONO Database
- Is the Addition of Oral Biotin to PRP More Beneficial for Treating Male Pattern Hair Loss Compared to PRP Alone? A Randomized Control Trial
- Is early onset androgenic alopecia a marker of metabolic syndrome and carotid artery atherosclerosis in young Indian male patients?
- Comparison of The Efficacy of Topical Cetirizine 1% Versus Topical Minoxidil 5% Solution in Treatment of Male Androgenetic Alopecia
- Assessing the Efficacy and Quality of Life Improvements of Botulinum Toxin Type A With Topical Minoxidil versus Topical Minoxidil in Male Androgenetic Alopecia: A Randomized Controlled Trial
- Evaluation of efficacy and safety of scalp threading with polydioxanone (PDO) monofilament threads in the treatment of male androgenetic alopecia
- A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia.
- An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)
- Long-term Clinical Outcomes of Autologous Non-activated Platelet-rich Plasma (A-PRP) Delivered Through Mechanical and Controlled Infiltration in Male and Female Androgenetic Alopecia: A 10-year Prospective Randomized Evaluator-blinded Study
- The Effect of Mesenchymal Stem Cells Derived-Conditioned Media in Combination with Oral Anti-Androgenic Drugs on Male Pattern Baldness: An Animal Study.
- Fractional Thulium Laser Combined with a Topical Growth Factor Serum Increases Hair Density and Thickness in Male and Female Androgenic Alopecia: A Pilot Study
- Pilot study: genetic distribution of AR, FGF5, SULT1A1 and CYP3A5 polymorphisms in male Mexican population with androgenetic alopecia.
- Early onset androgenic alopecia: not a cosmetic problem but a sign of life time risk factors. Male phenotypic equivalent of polycystic ovarian syndrome: Is There a Male Phenotype of PCOS
- Generation of an integration-free human induced pluripotent stem cell line MUSIi010-A from occipital scalp fibroblasts of a male patient with androgenetic alopecia
- New effects of caffeine on corticotropin‐releasing hormone (CRH)‐induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH‐R1/2, IP<sub>3</sub>‐R, ACTH, MC‐R2) and the neurogenic non‐HPA axis (substance P, p75<sup>NTR</sup>and TrkA) in<i>ex vivo</i>human male androgenetic scalp hair follicles
- An Uncontrolled Case Series Using a Botanically Derived, β-Cyclodextrin Inclusion Complex in Two Androgenetic Alopecia-Affected Male Subjects
- Faculty Opinions recommendation of A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
- A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia
- Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
- Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
- Short sequence repeats of the intergenic spacer regions of ribosomal RNA genes in <i>Malassezia globosa</i> and <i>M. restricta</i> colonizing the scalps of male individuals with and without androgenetic alopecia
- Female Androgenetic Alopecia: A Separate Entity
- Use of Minoxidil Sulfate versus Minoxidil Base in Androgenetic Alopecia Treatment: Friend or Foe?
- Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors
- Genetics and other factors in the aetiology of female pattern hair loss
- Early onset androgenetic alopecia in men and associated risk factors: a hospital based study
- Prevalence of early-onset androgenetic alopecia and its relation with lifestyle and dietary habits
- Hair Loss: A Harbinger of the Morbidities to Come!
- Assessment of adipokines, hormonal profile, lipid profile, and insulin resistance in patients with androgenetic alopecia
- Androgenetic Alopecia: An Evidence-Based Treatment Update